Abstract library

704 results for "response evaluation".
#2993 Proposal of New Imaging Criteria for Evaluating the Response of Liver Metastases to Systemic Treatments in Digestive Neuroendocrine Tumors (NET) as an Alternative to RECIST 1.1
Introduction: RECIST 1.1 criteria have been challenged for the evaluation of treatment response in NET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Louis de Mestier
#2748 CT-Based Radiomics for Prediction of Outcome after Somatostatin Analogues in Patients with Liver Metastases of a Neuroendocrine Tumor: An Exploratory Study
Introduction: Response evaluation and prediction of outcome of a neuroendocrine tumor (NET) remains difficult.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Femke Staal
#2897 Comparison of 68Ga-DOTATATE PET/CT for Assessment of Response to Peptide Receptor Radionuclide Therapy after 2 and 4 Cycles of 177Lu-DOTATATE: Preliminary Single Academic Center Experience
Introduction: Peptide receptor radionuclide therapy (PRRT) usually leads to stable rather than decreased lesion size in neuroendocrine tumors (NETs), therefore RECIST criteria are not used to assess early response to treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Hong Song
Authors: Song H, Kunz P, Fisher G, Franc B, ...
#2868 Differential Gene Expression May Predict Response to Somatostatin Analogues (SSAs) in Gastrointestinal (GI) Neuroendocrine Tumors (NETs)
Introduction: SSAs are commonly used to treat GI NETs as they have anti-secretory and antiproliferative effects. However, genetic markers predicting response to SSAs are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Prof. Dr. Dr. Andreas Teufel
Authors: Teufel A, Evert K, Itzel T, Evert M, ...
#2890 Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)
Introduction: Peptide receptor radionuclide therapy (PRRT) is an encouraging systemic treatment for neuroendocrine tumors (NET). PRRT is generally safe and possesses little side effects but little is known about liver toxicity.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Heying Duan
Authors: Duan H, Girod B, Ninatti G, Ferri V, ...
Keywords: NET, PRRT, Toxicity
#2820 Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma
Introduction: Esthesioneuroblastoma (ENB) is a rare malignancy with limited therapeutic options when unresectable or metastatic. The overexpression of cell-surface somatostatin receptors in ENB is a potential molecular target making it amenable to peptide receptor radionuclide therapy (PRRT). High-level evidence supporting PRRT has been published for unresectable gastroenteropancreatic neuroendocrine tumours; however, data is limited for PRRT efficacy for ENB.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Olfat Kamel Hasan
#2847 Surgical and Survival Outcomes of Early Peptide Receptor Radionuclide Therapy for Downstaging Locally Advanced or Oligometastatic Pancreatic Neuroendocrine Neoplasms
Introduction: Pancreatic neuroendocrine neoplasm (pNEN) patients often present with locally advanced or metastatic disease. The objective response rate of peptide receptor radionuclide therapy (PRRT) in pNENs is 55%. Therefore, PRRT may be a possibility for patients who are not eligible for upfront curative surgery.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Noémie S Minczeles
#3001 Early Response Assessment for Prediction of Overall Survival after Peptide Receptor Radionuclide Therapy
Introduction: PRRT response assessment is performed using RECIST, yet functional assessment using 68Ga-DOTATATE PET/CT and plasma CgA might give additional information about prediction of overall survival (OS).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Daphne Huizing
#2875 Immunotherapy as Second-line Treatment in Grade 3 Neuroendocrine Carcinomas: A Prospective Case Series from an ENETS Center of Excellence
Introduction: Metastatic WHO grade 3 extra-pulmonary neuroendocrine carcinomas (EP-NEC) have a poor prognosis and optimal treatment after first-line platinum-etoposide chemotherapy remains unclear. A recent, small phase II study combining ipilimumab and nivolumab showed promising results
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Timon Vandamme
Keywords: NEC, immunotherapy
#2987 68Ga-DOTATOC PET/CT as Tool for Diagnosis and Decision-Making Process of Neuroendocrine Tumors
Introduction: Primary tumors in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Inmaculada Peiró Martínez